Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women

2001 ◽  
Vol 100 (2) ◽  
pp. 207 ◽  
Author(s):  
Helena J. TEEDE ◽  
Barry P. MCGRATH ◽  
Alan TURNER ◽  
Harry MAJEWSKI
Keyword(s):  
Hormone Replacement Therapy ◽  
Platelet Aggregation ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement

Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women

2001 ◽  
Vol 100 (2) ◽  
pp. 207-213 ◽  
Author(s):  
Helena J. TEEDE ◽  
Barry P. MCGRATH ◽  
Alan TURNER ◽  
Harry MAJEWSKI
Keyword(s):  
Nitric Oxide ◽  
Arachidonic Acid ◽  
Placebo Group ◽  
Hormone Replacement Therapy ◽  
Platelet Aggregation ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Whole Blood ◽  
Hormone Replacement ◽  
Impedance Aggregometry

The effects of combined oestrogen/progestin hormone replacement therapy (HRT) on platelet aggregation were studied using women on HRT or placebo. The study involved 32 postmenopausal women (aged 50–75 years) who were enrolled in a double-blind randomized controlled trial, and who received either oral continuous combined HRT (Kliogest®; 2 mg of oestradiol+1 mg of norethisterone) or placebo for a minimum of 6 months. Platelet aggregation was measured by whole-blood impedance aggregometry in response to the agonists collagen, arachidonic acid and ADP. To determine whether the effects of oestrogen on platelets were influenced by platelet-derived nitric oxide, exposure to collagen was repeated in the presence of the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA). Mean platelet volume was similar in the two groups. Compared with the placebo group, the women on HRT had similar rates and maximum values of platelet aggregation in response to collagen, arachidonic acid and ADP. Addition of L-NMMA did not alter the aggregation response to collagen in either the HRT or the placebo group. In conclusion, postmenopausal women on oral combined continuous HRT comprising oestradiol and norethisterone had similar whole-blood platelet aggregation rates and maximum platelet aggregation responses to higher doses of platelet agonists when compared with those on placebo. The endogenous platelet nitric oxide system did not appear to affect aggregation in either group.

The effects of conjugated equine estrogens plus cyclical dydrogesterone on serum lipoproteins and apoproteins in postmenopausal women

1988 ◽  
Vol 117 (3) ◽  
pp. 339-342 ◽  
Author(s):  
C. D. Fletcher ◽  
E. Farish ◽  
M. M. Dagen ◽  
F. Alazzawi ◽  
D. McQueen ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Hdl Cholesterol ◽  
Serum Lipoproteins ◽  
Conjugated Equine Estrogens ◽  
The Individual ◽  
Equine Estrogens

Abstract. erum lipoprotein and apoprotein concentrations were monitored for 24 weeks in 26 postmenopausal women treated with conjugated equine estrogens (0.625 mg/day) with the addition of dydrogesterone (10 mg/day) for the last 12 days of each 28 day cycle. The women had had no previous hormone replacement therapy. The estrogen plus dydrogesterone regimen caused significant (P < 0.05) increases in triacylglycerol and HDL cholesterol concentrations. Both HDL2 and HDL3 cholesterol were increased. There were no other significant changes in lipoprotein concentrations. Both apoprotein AI and apoprotein All concentrations increased significantly (P < 0.05) over the study period. The ratios of apoprotein AI to apoprotein All, apoprotein AI to HDL cholesterol and apoprotein All to HDL cholesterol did not change. At the doses employed in this study, the use of dydrogesterone as a progestogen alters the effects of conjugated equine estrogens on lipoproteins and reinforces the view that the effects of a combined HRT regimen cannot be predicted from a consideration of the effects of the individual components.

Sign in / Sign up

Export Citation Format

Share Document